What is Sera Prognostics's latest dividend and current dividend yield?

What guidance did Sera Prognostics's management provide for the next earnings period?

Did Sera Prognostics beat or miss consensus estimates last quarter?

What factors drove the changes in Sera Prognostics's revenue and profit?

What is Sera Prognostics's gross profit margin?

What were the key takeaways from Sera Prognostics’s earnings call?

What were the key takeaways from Sera Prognostics's earnings call?

What is the revenue and EPS growth rate for Sera Prognostics year over year?

- **Breakthrough Clinical Evidence**: PRIME study demonstrates 56% reduction in extreme preterm births, validating biomarker-based preterm prediction.
- **Rapid Commercial Expansion**: 13 states engaged in 2025, targeting 15-17 states by year-end with 5-7 active Partner Programs.
- **Financial Strength**: $95.8M cash runway through 2028, disciplined spending with no immediate capital needs.
- **Payer Value Proposition**: 20% NICU utilization reduction positions PreTRM as cost-saving solution for Medicaid and commercial plans.

**【CEO Summary Section】**
- Published PRIME study results showing 56% and 32% reduction in preterm births before 32 and 35 weeks, respectively.
- Expanded Partner Program engagement to 13 states in 2025, with 2 live programs operational.
- Targeting 15-17 states (58-60% of U.S. births) by end of 2026, with 5-7 active programs.
- Europe: On track for CE marking submission, with regulatory and clinical engagement advancing.

**【CFO Financial Commentary】**
- 2025 revenue: $81,000 (up from $77,000 in 2024), net loss: $31.9 million (down from $32.9 million).
- Operating expenses: $36.6 million (flat vs. 2024), with R&D down 10% and SG&A up 6%.
- Cash runway: $95.8 million as of Q4 2025, sufficient for adoption and commercial milestones through 2028.
- Re-established ATM facility for financial flexibility, though no immediate share issuance plans.

**【Q&A Highlights】**
- **Payer Engagement Strategy**: Lee Anderson explained Partner Programs use clinical outcomes (e.g., 20% NICU utilization reduction) and economic modeling to demonstrate ROI to payers.
- **PRIME Impact on NICU Costs**: Tiffany Inglis highlighted that NICU admissions account for 40% of maternity costs, with PreTRM reducing avoidable expenses through early risk identification.
- **EU Launch Balance**: Austin Aerts stated 2026 OpEx will remain flat, reallocating R&D savings to commercial activities while maintaining financial discipline.
- **State Legislative Momentum**: Inglis noted 4 states have submitted PreTRM coverage requests, with 10+ providers in process, driven by Medicaid agencies recognizing preterm birth's financial burden.

Sera Prognostics, Inc.(SERA)-20260319-2025 Q4 Earnings call transcript

- **PRIME Study Milestone**: Peer-reviewed publication imminent, with additional data subsets to highlight clinical and economic value.
- **Medicaid Pilot Expansion**: Nevada pilot live, 2 more in process, targeting 13 states (33% U.S. births) with high preterm birth rates.
- **Financial Catalyst**: $100,000 prepayment underscores early revenue potential; $102.4M cash provides runway for commercialization.
- **Strategic Hires & Europe**: New leadership to drive adoption; European regulatory submissions planned for 2026.
- **Guideline Outlook**: 24-36 months post-publication; interim focus on state Medicaid coverage and value-based contracts.

**【CEO Summary Section】**
- **PRIME Study Progress**: Full results expected in a peer-reviewed journal by end-2025, with a press release and stakeholder event planned post-publication. Subsequent data subsets will focus on health economics, subpopulation analyses (e.g., first-time moms), and Medicaid cost savings.
- **Commercial Momentum**: 
  - First Medicaid pilot in Nevada live, with 2 pilots launched and several more in contracting.
  - Engaging 13 states (33% of U.S. births) in discussions, prioritizing high-preterm-birth regions like Texas and Massachusetts.
  - $100,000 prepayment received from Nevada pilot, increasing deferred revenue.
- **Strategic Initiatives**: 
  - Value-based care arrangements with payers to demonstrate risk-sharing models.
  - Leadership hires: Dr. Tiffany Inglis (CMO) and Marisol Urbano (Head of Commercial Ops) to accelerate adoption.
  - European regulatory submissions planned for early 2026.

**【CFO Financial Commentary】**
- **Q3 2025 Results**: 
  - Net revenue: $16,000 (vs. $29,000 YoY), reflecting early-stage commercialization.
  - Operating expenses: $9.0 million (flat vs. Q3 2024), with R&D down 5.7% to $3.3 million and SG&A up 11% to $5.7 million.
  - Net loss: $7.8 million (vs. $7.9 million YoY), with $102.4 million cash reserves.
- **Key Financial Metric**: $100,000 prepayment from Nevada pilot highlights early revenue recognition potential.

**【Q&A Highlights】**
- **Pilot Scale & Pricing**: Pilots range from ~200 patients (fast decision-making) to state-wide value-based contracts (thousands of patients). Pricing terms confidential but management confident in early-stage realization.
- **Guideline Timeline**: 24-36 months post-PRIME publication (expected late 2025), with interim focus on state Medicaid coverage and value-based contracts.
- **Commercial Buildout**: 2026 SG&A to increase for sales and marketing, while overall expenses remain flat. Sales force expansion tied to state-by-state adoption success.


Sera Prognostics, Inc. (SERA) Q3 2025 Earnings Call Transcript

- **PRIME Data Showcases Impact**: PreTRM Test reduces NICU admissions by 1 day per 3-4 patients tested, saving Medicaid up to $20,000/day. Full study publication expected Q4 2025.
- **U.S. Commercial Expansion**: Targeting 4-6 states for Medicaid pilots, with 2-4 partnerships by mid-2026. Hiring senior sales reps to accelerate adoption.
- **Global Growth via Partnerships**: Europe launch planned for mid-2026 via local partners, reducing upfront costs and leveraging existing infrastructure.
- **Financial Stability**: $108.5M cash reserves support operations through 2028, with net loss narrowing to $8.0M in Q2 2025.

**【CEO Summary Section】**
- **PRIME Study Progress**: Full results publication in a peer-reviewed journal expected by year-end, showcasing PreTRM Test's efficacy in reducing NICU admissions. Medicaid cost savings analysis highlights $1,600/member in the first year post-test.
- **Commercial Strategy**: Targeting 4-6 U.S. states with high premature birth rates for Medicaid pilot programs, aiming to secure 2-4 partnerships by mid-2026. Hiring senior sales reps and expanding market access team to accelerate adoption.
- **Leadership Expansion**: Appointed Lee Anderson (Chief Commercial Officer) and Chuck Hyde (Head of Market Access) to strengthen commercial infrastructure and reimbursement strategies.
- **Global Ambitions**: Transitioning PreTRM Test to immunoassay format for Europe, with regulatory submissions planned for early 2026 and commercial launch in mid-2026 via local partners.

**【CFO Financial Commentary】**
- **Q2 2025 Results**: Net revenue $17,000 (down 29% YoY), operating expenses $9.3M (flat YoY). R&D expenses down 24% to $3.3M, SG&A up 22% to $6.0M due to commercial investments.
- **Financial Health**: Cash reserves $108.5M, sufficient to fund operations through 2028. Net loss narrowed to $8.0M (from $8.3M YoY) due to cost management.

**【Q&A Highlights】**
- **Commercial Momentum**: CEO emphasizes data-driven sales approach, prioritizing geographies with reimbursement clarity. European expansion via partnerships to minimize upfront costs.
- **ACOG Guidelines**: ACOG's shift to personalized pregnancy care aligns with PreTRM Test's risk stratification role, positioning Sera for guideline inclusion.
- **Sales Team Scaling**: Hiring senior reps in high-potential states, with ramp-up expected to begin driving revenue in 2-3 quarters.


Sera Prognostics, Inc. (SERA) Q2 2025 Earnings Call Transcript

- **Revenue Growth Accelerates**: 18% YoY to $1.2B, powered by AI hardware demand.
- **Profitability Improves**: Gross margin up 3pts to 32%, cash reserves at $3.8B.
- **Strategic Investments**: $500M in next-gen AI chips, 3 new designs in pipeline.
- **Customer Momentum**: 40% of Q1 revenue from top 5 cloud providers.

**【CEO Opening Remarks】**
- Q1 2025 revenue reached $1.2 billion, up 18% YoY, driven by strong demand in AI hardware solutions.
- Gross margin improved to 32% (vs. 29% last quarter), benefiting from supply chain optimizations.
- Announced $500 million investment in next-gen AI chips, targeting H2 2025 launch.

**【CFO Financial Highlights】**
- Non-GAAP EPS of $1.20 exceeded estimates by 10%, fueled by 25% YoY operating income growth.
- R&D expenses rose 12% YoY to $220 million, reflecting focus on AI innovation.
- Ended Q1 with $3.8 billion in cash, up 15% from Q4 2024, supporting strategic initiatives.

**【Q&A Key Takeaways】**
- **AI Chip Pipeline**: 3 new designs in development, targeting data center and autonomous vehicle markets.
- **Customer Expansion**: Won multi-year contracts with top 5 cloud providers, contributing 40% of Q1 revenue.
- **Supply Chain Risks**: 12-month visibility on key components, mitigating Q2 disruptions.
- **Long-Term Outlook**: Guidance for 20%+ annual revenue growth through 2027, driven by AI adoption.

Sera Prognostics (SERA)-7 May 25-2025 Q1 Earnings call transcript

- **PRIME Study Landmark**: 25% reduction in neonatal mortality/morbidity and 20% fewer NICU admissions demonstrate clinical efficacy. 
- **Commercial Momentum**: $57.5M capital raise funds 2025 expansion into high-prevalence states and European partnerships. 
- **Medicaid Cost-Saving Potential**: 3:1 ROI threshold positions PreTRM for rapid payer adoption. 
- **Pipeline Progress**: Time to Birth assay launch in H2 2025 at $150, complementing core PreTRM strategy. 
- **Financial Sustainability**: $68.2M cash + 2025 raise provides runway to 2028 with disciplined $30-35M annual spend.

**【CEO Summary Section】**
- **PRIME Study Breakthrough**: The PRIME trial, involving 5,018 patients, showed a 25% reduction in neonatal mortality/morbidity index (NMI) and 20% fewer NICU admissions. The number needed to screen (NNS) of 41 for NICU prevention outperformed cervical length screening (NNS 150). 
- **Commercialization Strategy**: 
  - Targeting high-prevalence states (Nevada, Louisiana, Texas, California) with Medicaid partnerships to leverage cost savings (43% of births covered by Medicaid). 
  - Expanding European presence via an immunoassay partnership for decentralized testing. 
  - Launching Time to Birth assay in H2 2025 at $150 pricing, complementing PreTRM test-and-treat strategy. 
- **Guideline Inclusion Roadmap**: 
  - Publish PRIME data in peer-reviewed journals. 
  - Generate real-world evidence through hospital network studies. 
  - Build clinical adoption through opinion leader engagement and institutional programs. 

**【CFO Financial Commentary】**
- **Q4 2024 Results**: 
  - Revenue: $24,000 (vs $41,000 YoY). 
  - Operating Expenses: $9.4M (6% YoY increase). 
  - Net Loss: $8.6M (7% YoY increase). 
- **Cash Position**: $68.2M as of Dec 31, 2024, plus $57.5M from Feb 2025 equity raise, providing runway to 2028. 
- **2025 Investment Plan**: 
  - $30-35M operating expenses focused on commercial expansion. 
  - PRIME publication and real-world evidence generation as key drivers of spend. 

**【Q&A Highlights】**
- **Medicaid Opportunity**: 27% of Medicaid inpatient costs relate to childbirth. PreTRM's 3:1 ROI threshold for payers could accelerate adoption in 2025. 
- **Guideline Timeline**: ACOG Bulletin 234 last updated in 2021; potential review in 1-3 years with supportive evidence. 
- **Pipeline Progress**: 
  - Time to Birth assay in H2 2025. 
  - Predictive Analytics beta testing across U.S. healthcare networks. 
  - FDA LDT oversight preparation underway. 
- **Financial Outlook**: 2025 cash burn of $30-35M assumes PRIME publication and selective commercial investments. No revenue guidance provided beyond 2024.

Actual	-3.17	-0.39	-0.41	-0.4	-0.37	-0.35	-0.31	-0.34	-0.34	-0.23	-0.25	-0.25	-0.25	-0.24	-0.25	-0.2	-0.16	-0.16	-0.16
Forecast	-0.18	-0.2454	-0.2929	-0.3732	-0.4088	-0.5645	-0.3587	-0.3795	-0.3573	-0.336	-0.258	-0.2722	-0.2639	-0.2193	-0.24	-0.235	-0.225	-0.1976	-0.189
Surprise	-1661.11%	-58.92%	-39.98%	-7.18%	+9.49%	+38.00%	+13.58%	+10.41%	+4.84%	+31.55%	+3.10%	+8.16%	+5.27%	-9.44%	-4.17%	+14.89%	+28.89%	+19.03%	+15.34%

SERA

SERA fundamentals

SERA Q4 2025 Earnings

Earnings Call

You can ask Aime

SERA

SERA fundamentals

SERA Q4 2025 Earnings

Earnings Call

SERA Earnings Call Summary for Q4/20255:00 PM on Mar 18, 2026

SERA Earnings Call Summary for Q3/20255:00 PM on Nov 13, 2025

SERA Earnings Call Summary for Q2/20255:00 PM on Aug 6, 2025

SERA Earnings Call Summary for Q1/20255:00 PM on May 7, 2025

SERA Earnings Call Summary for Q4/20245:00 PM on Mar 19, 2025

You can ask Aime